The first clinical procedure was performed by Adrian Ebner, MD, the Head of the Cardiovascular Department at Sanatorio Italiano Hospital in Asuncion, Paraguay.
This stock-for-stock merger transaction in which Flow Forward Medical merged with and into Artio was approved by the Board of Directors and stockholders of both companies. The transaction closed on June 8, 2020.
The interim data demonstrated that use of the Endura™ Embolization System in bifurcation aneurysms can result in greater aneurysm occlusion and lower coil prolapse into parent arteries when compared to commercially available coil-only treatments.
Artio Medical was founded in 2014 as a small R&D group focused on developing metal implants for vascular embolization.
Metactive also announced the closing of $1.5 million of additional Series A financing, co-led by Mid-America Angels, with the participation of a family office and additional individual investors. Metactive previously raised $7.5 million in Series A funding, bringing the total funding raised to $9 million.